Reported Tuesday, Oct 6 - 9:07am EDT (TheFly subscription required to read more.)

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Conexeu will present in New York and participate in Munich; it anticipates a 510(k) submission in early 2027, subject to regulatory review.

A potential new category in soft-tissue restoration. B.R.E.A.S.T.™ applies the CXU™ platform to breast reconstruction beyond implants. Preclinical stage.

Conexeu Sciences (Nasdaq: CNXU), a preclinical-stage regenerative tissue platform company, highlights the emergence of a new medical aesthetics category focused on regenerative soft-tissue restoration, centered on the extracellular matrix (ECM). Independent research cited by Conexeu sizes the bioregenerative aesthetics segment at about $1.6 billion in 2025 with projected annual growth above 11%, within a broader regenerative aesthetics market estimated at $15.6 billion.Conexeu’s patented CXU™ ECM platform is designed as a multi-component collagen-ECM scaffold and underpins its lead device candidate, Ten-Minute Tissue™, a thermosensitive ECM material that gels in situ at body temperature in about ten minutes. The company recently completed the 12‑month P.R.O.O.F. preclinical phase, which met predefined objectives in small-volume facial and approximately 200cc-equivalent large-volume subcutaneous tissue models, while noting these volumes do not establish appropriate or safe human dosing. Conexeu holds a multi-jurisdictional patent estate spanning more than 40 jurisdictions and is pursuing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027 for its initial indication, subject to regulatory review.

By Robert Kiyosaki

Conexeu (Nasdaq: CNXU) announced that Chief Medical Officer Dr. Brian Pilcher will give an industry presentation at the 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium, held August 14–16, 2026. His August 15 talk, “Beyond Filling: An Extracellular Matrix Blueprint for Tissue Regeneration,” will focus on the role of the extracellular matrix (ECM) in tissue regeneration and regenerative aesthetics.The presentation aligns with Conexeu’s preclinical CXU™ ECM platform and its lead thermosensitive device candidate, Ten-Minute Tissue™, which is designed to support soft-tissue restoration and is supported by multiple peer‑reviewed preclinical studies.

Read the latest about Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison at FinancialFreedomHawaii.com

Read the latest about Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison at FinancialFreedomHawaii.com

Conexeu Sciences (NASDAQ:CNXU – Get Free Report) is one of 27 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its peers? We will compare Conexeu Sciences to related companies based on the strength of its valuation, profitability, earnings, risk, institutional ownership, analyst recommendations and dividends. [...]

The GLP-1 weight-loss surge has opened a lucrative $2 billion aesthetic market. Conexeu Sciences Inc. aims to fill this gap with innovative bioregenerative solutions.

Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) is aiming its investigational CXU™ platform at the largest unclaimed frontier in injectable aesthetics: restoring real body volume at a scale today's fillers were never built to reach, a move built on the...

YouTube video by Investor TV

Conexeu Sciences Inc. has achieved a key milestone in its preclinical program, advancing its CXU platform for applications in medical aesthetics. This breakthrough paves the way for future developments.

Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) completed the 12-month P.R.O.O.F phase of its CXU preclinical program, which met its objectives across three pillars, facial, body, and mechanical performance, as it advances a single-formulation regenerative...